Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Optimisation of cyclophosphamide therapy in systemic vasculitis

R Richmond1, T W McMillan, R A Luqmani

  • 1Department of Rheumatology, University of Edinburgh, Scotland.

Clinical Pharmacokinetics
|February 25, 1998
PubMed
Summary

Cyclophosphamide improves prognosis for systemic vasculitides but causes toxicity. Balancing its effectiveness and side effects is crucial for long-term survival in patients with this autoimmune disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical features and structured clinical evaluation of vasculitis.

Best practice & research. Clinical rheumatology·2018
Same author

Maintaining abstinence from smoking after a period of enforced abstinence: considerations of non-compliance and the significance of reduced smoking [Psychological Medicine, 2018, 48, 669-678].

Psychological medicine·2018
Same author

Maternal and fetal genetic contribution to gestational weight gain.

International journal of obesity (2005)·2017
Same author

Addressing the arguments against implementation of smoke-free policies in psychiatric facilities.

Journal of psychiatric and mental health nursing·2017
Same author

EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis.

Annals of the rheumatic diseases·2016
Same author

Withdrawn: Misuse of Tri-solfen in cattle is a concern for export industry.

Australian veterinary journal·2015

Area of Science:

  • Rheumatology
  • Immunology
  • Pharmacology

Background:

  • Systemic vasculitides prognosis improved with immunosuppressants like cyclophosphamide.
  • Chronic disease, relapse, and therapy toxicity pose significant burdens.
  • Current treatment involves intensive induction followed by maintenance therapy.

Purpose of the Study:

  • To review the role of cyclophosphamide in managing systemic vasculitides.
  • To discuss the challenges in balancing treatment effectiveness and toxicity.
  • To explore potential future therapeutic strategies.

Main Methods:

  • Review of existing literature and clinical trial evidence on cyclophosphamide regimens.
  • Analysis of treatment strategies for inducing remission and maintenance.

Related Experiment Videos

  • Consideration of pathogenetic mechanisms and novel therapeutic approaches.

    • Main Results:

    • Cyclophosphamide is the preferred drug despite diverse pathogenetic mechanisms.
    • Evidence does not support significant outcome differences between cyclophosphamide regimens.
    • Balancing efficacy and toxicity remains a challenge for long-term survival.

    Conclusions:

    • Optimizing cyclophosphamide use requires balancing effectiveness with toxicity.
    • Future research should focus on targeted therapies and alternative approaches like bone marrow rescue.
    • Improving long-term quality of survival in vasculitis patients is an ongoing goal.